EFL-301 is a promising therapeutic target drug by having antifibrotic effects in various organs such as liver, lung, kidney, heart and skin in ongoing fibrosis and fibrosis regression which is the final pathological outcome of most chronic inflammatory diseases. EFL-301 has the potential to be a disease-modifying therapy by inhibiting collagen accumulation and TGF-β signaling and to be extended to other indications as well.